Lixisenatide (trade name Lyxumia in the Europe and Adlyxin in the U.S.) is a once-daily injectable GLP-1 receptor agonist for the treatment of diabetes type II. Initiate at 10 mcg once daily for 14 days. On Day 15, increase dosage to 20 mcg once daily...Wikipedia

 

 

Manufacturer's Website: Adlyxin                                                                                                                     Average retail cost: $578/month

 

Search Terms: Adlyxin, lixisenatide, GLP-1 receptor, diabetes type II